Review



pakt 5473  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc pakt 5473
    Pakt 5473, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 43 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+src/Phospho-Src+(Ser17)+Antibody/us12594421-308-43-46
    Average 94 stars, based on 43 article reviews
    pakt 5473 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    other:

    Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
    Article Snippet: Primary antibodies are used as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F-10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti-phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05–104, Sigma-Aldrich), anti-8-OHdG (sc-66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); PHA-665,752 (S1070; TargetMol), Dasatinib (CDS023389; Sigma-Aldrich), ML-385 (S8790; Selleckchem), Paclitaxel (T7191; Sigma-Aldrich);

    Fractionation:

    Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer.
    Article Snippet: .. Primary antibodies used are as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti- AR TIC LE IN PR ES S phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05-104, Sigma-Aldrich), anti-8-OHdG (sc66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); PHA-665752 (S1070; TargetMol), Dasatinib (CDS023389; Sigma-Aldrich), ML-385 (S8790; Selleckchem), Paclitaxel (T7191; Sigma-Aldrich); Protein extract, nuclei/cytoplasm fractionation and western blot analyses Total protein lysates were prepared using Buffer A (10 mM Hepes [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.1% NP-40) or RIPA Buffer (50mM Tris-HCL pH 8.0, 150mM NaCl, 1% NP40, 12mM sodium deoxycholate) supplemented with 10 mg/ml Protease Inhibitor Cocktail-1 (P2714; Sigma-Aldrich), 10 mg/mL TPCK, 1mM phenylmethylsulfonyl fluoride, 25mM NaF, 1mM sodium orthovanadate, 25 mM β-glycerophosphate. ..

    Western Blot:

    Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer.
    Article Snippet: .. Primary antibodies used are as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti- AR TIC LE IN PR ES S phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05-104, Sigma-Aldrich), anti-8-OHdG (sc66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); PHA-665752 (S1070; TargetMol), Dasatinib (CDS023389; Sigma-Aldrich), ML-385 (S8790; Selleckchem), Paclitaxel (T7191; Sigma-Aldrich); Protein extract, nuclei/cytoplasm fractionation and western blot analyses Total protein lysates were prepared using Buffer A (10 mM Hepes [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.1% NP-40) or RIPA Buffer (50mM Tris-HCL pH 8.0, 150mM NaCl, 1% NP40, 12mM sodium deoxycholate) supplemented with 10 mg/ml Protease Inhibitor Cocktail-1 (P2714; Sigma-Aldrich), 10 mg/mL TPCK, 1mM phenylmethylsulfonyl fluoride, 25mM NaF, 1mM sodium orthovanadate, 25 mM β-glycerophosphate. ..

    Article Title: Application of a novel myristoylproteomics approach identifies GLIPR2 as a key pro-ferroptotic substrate in non-small cell lung cancer.
    Article Snippet: .. The primary antibodies used for SDS-PAGE and western blot were as follows: anti-NMT1 (abcam, #ab186123; 1:1000, Cambridge, Cambs, UK), antiNMT2 (abcam, #ab224045; 1:1000), anti-ACTB (Servicebio, #GB12001-100; 1:3000, Wuhan, Hubei, China), anti-GAPDH (Servicebio, #GB12002-100; 1:3000), anti-TAMRA (abcam, #ab171120; 1:1000), anti-PRKACA (Cell Signaling Technology, #5842S; 1:500, Danvers, MA, USA), anti-SRC (Cell Signaling Technology, #2123; 1:500), anti-CHCHD3 (abcam, #ab224565; 1:1000), anti-FSP1 (SANTA CRUZ, #sc-377120; 1:1000, Dallas, TX, USA), anti-GLIPR2 (SANTA CRUZ, #sc-398529; 1:500), anti-GLIPR2 (abcam, #ab122059; 1:250), anti-OCC1 (Thermo Scientific, #PA5-20673; 1:500, Waltham, MA, USA), anti-RFTN1 (Proteintech, 24289-1-AP; 1:2000, Chicago, IL, USA), and anti-FLAG (Thermo Scientific, #MA1-91878; 1:1000), antiSLC7A11 (ABclonal, A2413, 1:2000, Wuhan, China), anti-LPCAT3 (Proteintech, 67882-1-Ig, 1:1000), anti-ACSL4 (Proteintech, 22401-1- AP, 1:5000), anti-GPX4 (Proteintech, 67763-1-Ig, 1:2000), anti-FTH (ABclonal, A1144, 1:1000), anti-FTL (ABclonal, A1768, 1:1000), antiTFRC (Proteintech, 84766-4-RR, 1:2000). .. The primary antibodies used for IHC were anti‐4‐HNE antibody (abcam, #48506).

    Article Title: Application of a novel myristoylproteomics approach identifies GLIPR2 as a key pro-ferroptotic substrate in non-small cell lung cancer
    Article Snippet: .. The primary antibodies used for SDS-PAGE and western blot were as follows: anti-NMT1 (abcam, #ab186123; 1:1000, Cambridge, Cambs, UK), anti-NMT2 (abcam, #ab224045; 1:1000), anti-ACTB (Servicebio, #GB12001-100; 1:3000, Wuhan, Hubei, China), anti-GAPDH (Servicebio, #GB12002-100; 1:3000), anti-TAMRA (abcam, #ab171120; 1:1000), anti-PRKACA (Cell Signaling Technology, #5842S; 1:500, Danvers, MA, USA), anti-SRC (Cell Signaling Technology, #2123; 1:500), anti-CHCHD3 (abcam, #ab224565; 1:1000), anti-FSP1 (SANTA CRUZ, #sc-377120; 1:1000, Dallas, TX, USA), anti-GLIPR2 (SANTA CRUZ, #sc-398529; 1:500), anti-GLIPR2 (abcam, #ab122059; 1:250), anti-OCC1 (Thermo Scientific, #PA5-20673; 1:500, Waltham, MA, USA), anti-RFTN1 (Proteintech, 24289-1-AP; 1:2000, Chicago, IL, USA), and anti-FLAG (Thermo Scientific, #MA1-91878; 1:1000), anti-SLC7A11 (ABclonal, A2413, 1:2000, Wuhan, China), anti-LPCAT3 (Proteintech, 67882-1-Ig, 1:1000), anti-ACSL4 (Proteintech, 22401-1-AP, 1:5000), anti-GPX4 (Proteintech, 67763-1-Ig, 1:2000), anti-FTH (ABclonal, A1144, 1:1000), anti-FTL (ABclonal, A1768, 1:1000), anti-TFRC (Proteintech, 84766-4-RR, 1:2000). .. The primary antibodies used for IHC were anti‐4‐HNE antibody (abcam, #48506).

    Protease Inhibitor:

    Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer.
    Article Snippet: .. Primary antibodies used are as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti- AR TIC LE IN PR ES S phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05-104, Sigma-Aldrich), anti-8-OHdG (sc66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); PHA-665752 (S1070; TargetMol), Dasatinib (CDS023389; Sigma-Aldrich), ML-385 (S8790; Selleckchem), Paclitaxel (T7191; Sigma-Aldrich); Protein extract, nuclei/cytoplasm fractionation and western blot analyses Total protein lysates were prepared using Buffer A (10 mM Hepes [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.1% NP-40) or RIPA Buffer (50mM Tris-HCL pH 8.0, 150mM NaCl, 1% NP40, 12mM sodium deoxycholate) supplemented with 10 mg/ml Protease Inhibitor Cocktail-1 (P2714; Sigma-Aldrich), 10 mg/mL TPCK, 1mM phenylmethylsulfonyl fluoride, 25mM NaF, 1mM sodium orthovanadate, 25 mM β-glycerophosphate. ..

    Bioprocessing:

    Article Title: Role of lipid rafts in the FGFR2c-mediated oncogenic signaling by involvement of TRPA1 channel in pancreatic ductal adenocarcinoma cells.
    Article Snippet: The membranes were incubated with anti-Flotillin (Abcam Cambridge, UK; ab13493) anti-E-cadherin (GT311 GeneTex, Irvine, California, USA), anti-vimentin (M0725, Dako, Glostrup, Denmark), anti-phospho-Fibroblast Growth Factor Receptor Substrate 2 α (FRS2-α) (Tyr196) (Cell Signaling Technology, Beverly, MA, USA, 3864), the anti-phospho-Sarcoma kinase (Src) Family (Tyr416, D49G4) (Cell Signaling Technology, Beverly, MA; USA;6943), monoclonal antibodies anti-pMTOR (Ser 2448; Cell Signaling; Beverly, MA, USA; 5536S), anti-p-p44/42 mitogen-activated protein kinase (MAPK) (p-ERK1/2) (Thr202/Tyr204; Cell Signaling; 9101S), anti-Bek (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA; C17, sc-122), anti-p-S6K (ser 371, Cell Signaling, Beverly, MA, USA; 9208), and anti p-PKCε (Ser729, Abcam, Cambridge, UK; ab63387), anti-Myeloid Cell Leukemia 1 (Mcl-1) (D35A5) (Cell Signaling; Beverly, MA, USA; 5453), anti-TRPA1 (Abcam; Abcam Cambridge, UK; ab62053),. .. The membranes were stripped as reported [6] and probed again with anti-p44/42 MAPK (ERK1/2) (Cell Signaling; Beverly, MA, USA; 4695S), anti-S6K (Cell Signaling; Beverly, MA, USA;9202), anti-PKCε (Abcam; Abcam Cambridge, UK;ab124806), anti-FRS2 (H-91) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA; sc-8318), anti-HSP90 (Proteintech Inc., Rosemont, IL, USA, 13171-1-AP), antiMTOR (Cell Signaling; Beverly, MA, USA; 2983S) polyclonal antibodies or anti-Src (Cell Signaling; Beverly, MA, USA;36D10), anti-ACTB (Sigma-Aldrich; St. Louis, Missouri, USA; A5441) monoclonal antibodies for protein equal loading. ..

    SDS Page:

    Article Title: Application of a novel myristoylproteomics approach identifies GLIPR2 as a key pro-ferroptotic substrate in non-small cell lung cancer.
    Article Snippet: .. The primary antibodies used for SDS-PAGE and western blot were as follows: anti-NMT1 (abcam, #ab186123; 1:1000, Cambridge, Cambs, UK), antiNMT2 (abcam, #ab224045; 1:1000), anti-ACTB (Servicebio, #GB12001-100; 1:3000, Wuhan, Hubei, China), anti-GAPDH (Servicebio, #GB12002-100; 1:3000), anti-TAMRA (abcam, #ab171120; 1:1000), anti-PRKACA (Cell Signaling Technology, #5842S; 1:500, Danvers, MA, USA), anti-SRC (Cell Signaling Technology, #2123; 1:500), anti-CHCHD3 (abcam, #ab224565; 1:1000), anti-FSP1 (SANTA CRUZ, #sc-377120; 1:1000, Dallas, TX, USA), anti-GLIPR2 (SANTA CRUZ, #sc-398529; 1:500), anti-GLIPR2 (abcam, #ab122059; 1:250), anti-OCC1 (Thermo Scientific, #PA5-20673; 1:500, Waltham, MA, USA), anti-RFTN1 (Proteintech, 24289-1-AP; 1:2000, Chicago, IL, USA), and anti-FLAG (Thermo Scientific, #MA1-91878; 1:1000), antiSLC7A11 (ABclonal, A2413, 1:2000, Wuhan, China), anti-LPCAT3 (Proteintech, 67882-1-Ig, 1:1000), anti-ACSL4 (Proteintech, 22401-1- AP, 1:5000), anti-GPX4 (Proteintech, 67763-1-Ig, 1:2000), anti-FTH (ABclonal, A1144, 1:1000), anti-FTL (ABclonal, A1768, 1:1000), antiTFRC (Proteintech, 84766-4-RR, 1:2000). .. The primary antibodies used for IHC were anti‐4‐HNE antibody (abcam, #48506).

    Article Title: Application of a novel myristoylproteomics approach identifies GLIPR2 as a key pro-ferroptotic substrate in non-small cell lung cancer
    Article Snippet: .. The primary antibodies used for SDS-PAGE and western blot were as follows: anti-NMT1 (abcam, #ab186123; 1:1000, Cambridge, Cambs, UK), anti-NMT2 (abcam, #ab224045; 1:1000), anti-ACTB (Servicebio, #GB12001-100; 1:3000, Wuhan, Hubei, China), anti-GAPDH (Servicebio, #GB12002-100; 1:3000), anti-TAMRA (abcam, #ab171120; 1:1000), anti-PRKACA (Cell Signaling Technology, #5842S; 1:500, Danvers, MA, USA), anti-SRC (Cell Signaling Technology, #2123; 1:500), anti-CHCHD3 (abcam, #ab224565; 1:1000), anti-FSP1 (SANTA CRUZ, #sc-377120; 1:1000, Dallas, TX, USA), anti-GLIPR2 (SANTA CRUZ, #sc-398529; 1:500), anti-GLIPR2 (abcam, #ab122059; 1:250), anti-OCC1 (Thermo Scientific, #PA5-20673; 1:500, Waltham, MA, USA), anti-RFTN1 (Proteintech, 24289-1-AP; 1:2000, Chicago, IL, USA), and anti-FLAG (Thermo Scientific, #MA1-91878; 1:1000), anti-SLC7A11 (ABclonal, A2413, 1:2000, Wuhan, China), anti-LPCAT3 (Proteintech, 67882-1-Ig, 1:1000), anti-ACSL4 (Proteintech, 22401-1-AP, 1:5000), anti-GPX4 (Proteintech, 67763-1-Ig, 1:2000), anti-FTH (ABclonal, A1144, 1:1000), anti-FTL (ABclonal, A1768, 1:1000), anti-TFRC (Proteintech, 84766-4-RR, 1:2000). .. The primary antibodies used for IHC were anti‐4‐HNE antibody (abcam, #48506).



    Similar Products

    pakt 5473  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc pakt 5473
    Pakt 5473, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+src/Phospho-Src+(Ser17)+Antibody/us12594421-308-43-46
    Average 94 stars, based on 1 article reviews
    pakt 5473 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    phospho fak tyr397 3283s cell signaling src  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc phospho fak tyr397 3283s cell signaling src
    Phospho Fak Tyr397 3283s Cell Signaling Src, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+src/Phospho-FAK+(Tyr397)+Antibody/us12594421-308-56-59
    Average 96 stars, based on 1 article reviews
    phospho fak tyr397 3283s cell signaling src - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    phospho src tyr416  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc phospho src tyr416
    Phospho Src Tyr416, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+src/Phospho-Src+Family+(Tyr416)+Antibody/us12594421-308-66-69
    Average 96 stars, based on 1 article reviews
    phospho src tyr416 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    src 32g6 rabbit mab  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc src 32g6 rabbit mab
    Src 32g6 Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+src/bio_rxiv__64898__2026__04__02__716058-64-15-78
    Average 86 stars, based on 1 article reviews
    src 32g6 rabbit mab - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    phospho src family tyr416 d49g4 rabbit mab  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc phospho src family tyr416 d49g4 rabbit mab
    A Western blot analysis of the oral squamous carcinoma cell lines to monitor numerous signaling pathways. The phosphorylated and total protein levels were determined as indicated. B Cell viability (%) of the oral squamous carcinoma cell lines treated with each Src inhibitor for 72 h. Viability was measured using CellTiter-Glo, and values are indicated relative to the 1% dimethyl sulfoxide (DMSO) control. Data represent mean ± standard deviation from three independent experiments (n = 3). C IC50 curves of the oral squamous carcinoma cell lines treated with each Src inhibitor for 36 h. Viability was measured using CellTiter-Glo and normalized to that of the 1% DMSO control. Values represent the mean of n = 3. D, E Western blot analysis of the oral squamous carcinoma cell lines to investigate Src (D) and MAPK (E) activity induced by different Src inhibitors. Oral squamous carcinoma cell lines were treated with an Src inhibitor for 18 h, followed by western blot analysis. D indicates the Src phosphorylation <t>(Tyr416),</t> and E reveals MAPK pathway-related proteins. Supplementary Table S1 lists the concentrations of the Src inhibitors used.
    Phospho Src Family Tyr416 D49g4 Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+src/bio_rxiv__64898__2026__04__02__716058-74-6-39
    Average 86 stars, based on 1 article reviews
    phospho src family tyr416 d49g4 rabbit mab - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    immunodetection p src  (Abmart Inc)
    86
    Abmart Inc immunodetection p src
    A Western blot analysis of the oral squamous carcinoma cell lines to monitor numerous signaling pathways. The phosphorylated and total protein levels were determined as indicated. B Cell viability (%) of the oral squamous carcinoma cell lines treated with each Src inhibitor for 72 h. Viability was measured using CellTiter-Glo, and values are indicated relative to the 1% dimethyl sulfoxide (DMSO) control. Data represent mean ± standard deviation from three independent experiments (n = 3). C IC50 curves of the oral squamous carcinoma cell lines treated with each Src inhibitor for 36 h. Viability was measured using CellTiter-Glo and normalized to that of the 1% DMSO control. Values represent the mean of n = 3. D, E Western blot analysis of the oral squamous carcinoma cell lines to investigate Src (D) and MAPK (E) activity induced by different Src inhibitors. Oral squamous carcinoma cell lines were treated with an Src inhibitor for 18 h, followed by western blot analysis. D indicates the Src phosphorylation <t>(Tyr416),</t> and E reveals MAPK pathway-related proteins. Supplementary Table S1 lists the concentrations of the Src inhibitors used.
    Immunodetection P Src, supplied by Abmart Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+src/anti+immunodetection+p+src/pm41936835-117-7-9
    Average 86 stars, based on 1 article reviews
    immunodetection p src - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    src targeting sirna sc 5266  (Santa Cruz Biotechnology)
    97
    Santa Cruz Biotechnology src targeting sirna sc 5266
    A Western blot analysis of the oral squamous carcinoma cell lines to monitor numerous signaling pathways. The phosphorylated and total protein levels were determined as indicated. B Cell viability (%) of the oral squamous carcinoma cell lines treated with each Src inhibitor for 72 h. Viability was measured using CellTiter-Glo, and values are indicated relative to the 1% dimethyl sulfoxide (DMSO) control. Data represent mean ± standard deviation from three independent experiments (n = 3). C IC50 curves of the oral squamous carcinoma cell lines treated with each Src inhibitor for 36 h. Viability was measured using CellTiter-Glo and normalized to that of the 1% DMSO control. Values represent the mean of n = 3. D, E Western blot analysis of the oral squamous carcinoma cell lines to investigate Src (D) and MAPK (E) activity induced by different Src inhibitors. Oral squamous carcinoma cell lines were treated with an Src inhibitor for 18 h, followed by western blot analysis. D indicates the Src phosphorylation <t>(Tyr416),</t> and E reveals MAPK pathway-related proteins. Supplementary Table S1 lists the concentrations of the Src inhibitors used.
    Src Targeting Sirna Sc 5266, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+src/c-Src+Antibody/pmc13046926-253-2-8
    Average 97 stars, based on 1 article reviews
    src targeting sirna sc 5266 - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier
    src  (Proteintech)
    95
    Proteintech src
    A Western blot analysis of the oral squamous carcinoma cell lines to monitor numerous signaling pathways. The phosphorylated and total protein levels were determined as indicated. B Cell viability (%) of the oral squamous carcinoma cell lines treated with each Src inhibitor for 72 h. Viability was measured using CellTiter-Glo, and values are indicated relative to the 1% dimethyl sulfoxide (DMSO) control. Data represent mean ± standard deviation from three independent experiments (n = 3). C IC50 curves of the oral squamous carcinoma cell lines treated with each Src inhibitor for 36 h. Viability was measured using CellTiter-Glo and normalized to that of the 1% DMSO control. Values represent the mean of n = 3. D, E Western blot analysis of the oral squamous carcinoma cell lines to investigate Src (D) and MAPK (E) activity induced by different Src inhibitors. Oral squamous carcinoma cell lines were treated with an Src inhibitor for 18 h, followed by western blot analysis. D indicates the Src phosphorylation <t>(Tyr416),</t> and E reveals MAPK pathway-related proteins. Supplementary Table S1 lists the concentrations of the Src inhibitors used.
    Src, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+src/SRC+Antibody/pm41923217-130-27-28
    Average 95 stars, based on 1 article reviews
    src - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    p src  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc p src
    A Western blot analysis of the oral squamous carcinoma cell lines to monitor numerous signaling pathways. The phosphorylated and total protein levels were determined as indicated. B Cell viability (%) of the oral squamous carcinoma cell lines treated with each Src inhibitor for 72 h. Viability was measured using CellTiter-Glo, and values are indicated relative to the 1% dimethyl sulfoxide (DMSO) control. Data represent mean ± standard deviation from three independent experiments (n = 3). C IC50 curves of the oral squamous carcinoma cell lines treated with each Src inhibitor for 36 h. Viability was measured using CellTiter-Glo and normalized to that of the 1% DMSO control. Values represent the mean of n = 3. D, E Western blot analysis of the oral squamous carcinoma cell lines to investigate Src (D) and MAPK (E) activity induced by different Src inhibitors. Oral squamous carcinoma cell lines were treated with an Src inhibitor for 18 h, followed by western blot analysis. D indicates the Src phosphorylation <t>(Tyr416),</t> and E reveals MAPK pathway-related proteins. Supplementary Table S1 lists the concentrations of the Src inhibitors used.
    P Src, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+src/Phospho-Src+(Ser17)+Rabbit+mAb/pm41923217-130-22-23
    Average 94 stars, based on 1 article reviews
    p src - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    A Western blot analysis of the oral squamous carcinoma cell lines to monitor numerous signaling pathways. The phosphorylated and total protein levels were determined as indicated. B Cell viability (%) of the oral squamous carcinoma cell lines treated with each Src inhibitor for 72 h. Viability was measured using CellTiter-Glo, and values are indicated relative to the 1% dimethyl sulfoxide (DMSO) control. Data represent mean ± standard deviation from three independent experiments (n = 3). C IC50 curves of the oral squamous carcinoma cell lines treated with each Src inhibitor for 36 h. Viability was measured using CellTiter-Glo and normalized to that of the 1% DMSO control. Values represent the mean of n = 3. D, E Western blot analysis of the oral squamous carcinoma cell lines to investigate Src (D) and MAPK (E) activity induced by different Src inhibitors. Oral squamous carcinoma cell lines were treated with an Src inhibitor for 18 h, followed by western blot analysis. D indicates the Src phosphorylation (Tyr416), and E reveals MAPK pathway-related proteins. Supplementary Table S1 lists the concentrations of the Src inhibitors used.

    Journal: bioRxiv

    Article Title: Heterogeneous Sensitivity to Src Inhibitors in Oral Squamous Cell Carcinoma and Its Implications for Combination Therapy with Cisplatin

    doi: 10.64898/2026.04.02.716058

    Figure Lengend Snippet: A Western blot analysis of the oral squamous carcinoma cell lines to monitor numerous signaling pathways. The phosphorylated and total protein levels were determined as indicated. B Cell viability (%) of the oral squamous carcinoma cell lines treated with each Src inhibitor for 72 h. Viability was measured using CellTiter-Glo, and values are indicated relative to the 1% dimethyl sulfoxide (DMSO) control. Data represent mean ± standard deviation from three independent experiments (n = 3). C IC50 curves of the oral squamous carcinoma cell lines treated with each Src inhibitor for 36 h. Viability was measured using CellTiter-Glo and normalized to that of the 1% DMSO control. Values represent the mean of n = 3. D, E Western blot analysis of the oral squamous carcinoma cell lines to investigate Src (D) and MAPK (E) activity induced by different Src inhibitors. Oral squamous carcinoma cell lines were treated with an Src inhibitor for 18 h, followed by western blot analysis. D indicates the Src phosphorylation (Tyr416), and E reveals MAPK pathway-related proteins. Supplementary Table S1 lists the concentrations of the Src inhibitors used.

    Article Snippet: The following primary antibodies were used: Phospho-Src Family (Tyr416) (D49G4) Rabbit mAb (#6943), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP Rabbit mAb (#4370), Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP Rabbit mAb (#4511), and Phospho-SAPK/JNK (Thr183/Tyr185) (81E11) Rabbit mAb (#4668) (all from Cell Signaling Technology).

    Techniques: Western Blot, Protein-Protein interactions, Control, Standard Deviation, Activity Assay, Phospho-proteomics